Mostrar el registro sencillo del ítem

Artículo

dc.creatorCruz Merino, Luis de laes
dc.creatorPalazón Carrión, N.es
dc.creatorHenao-Carrasco, F.es
dc.creatorNogales-Fernández, E.es
dc.creatorÁlamo de la Gala, M.es
dc.creatorVallejo Benítez, A.es
dc.creatorChiesa, M.es
dc.date.accessioned2024-03-07T16:52:05Z
dc.date.available2024-03-07T16:52:05Z
dc.date.issued2019
dc.identifier.citationCruz Merino, L.d.l., Palazón Carrión, N., Henao-Carrasco, F., Nogales-Fernández, E., Álamo de la Gala, M., Vallejo Benítez, A. y Chiesa, M. (2019). New horizons in breast cancer: the promise of immunotherapy. Clinical and Translational Oncology, 21 (2), 117-125. https://doi.org/10.1007/s12094-018-1907-3.
dc.identifier.issn1699-048Xes
dc.identifier.issn1699-3055es
dc.identifier.urihttps://hdl.handle.net/11441/155950
dc.description.abstractImmunology and immunotherapy of cancer is an expanding feld in oncology, with recent great achievements obtained through the new successful approaches implemented to circumvent immune evasion, which is undoubtedly considered a novel hallmark of cancer. Translational research in this topic has revealed targets that can be modulated in the clinical setting with new compounds and strategies. Like most of the tumors, breast cancer is considered a complex and heterogeneous disease in which host immune responses have been also recently demonstrated of critical relevance. T infltrating lymphocyte measure ment is suggested as a powerful new tool necessary to predict early breast cancer evolution, especially for the her2-positive and triple-negative subtypes. Other biomarkers in tissue and peripheral blood are under intense scrutiny to ascertain their eventual role as prognostic and/or predictive factors. This background has fueled the interest in developing clinical research strategies to test activity of modern immunotherapy in breast cancer, which constitutes the main focus of this review.es
dc.formatapplication/pdfes
dc.format.extent9 p.es
dc.language.isoenges
dc.publisherSpringeres
dc.relation.ispartofClinical and Translational Oncology, 21 (2), 117-125.
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectBreastes
dc.subjectCanceres
dc.subjectImmunologyes
dc.subjectImmunotherapyes
dc.subjectClinicales
dc.subjectTrialses
dc.titleNew horizons in breast cancer: the promise of immunotherapyes
dc.typeinfo:eu-repo/semantics/articlees
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Bioquímica Médica y Biología Molecular e Inmunologíaes
dc.relation.publisherversionhttps://link.springer.com/article/10.1007/s12094-018-1907-3es
dc.identifier.doi10.1007/s12094-018-1907-3es
dc.contributor.groupUniversidad de Sevilla. CTS151: Bioquímica médica.es
dc.journaltitleClinical and Translational Oncologyes
dc.publication.volumen21es
dc.publication.issue2es
dc.publication.initialPage117es
dc.publication.endPage125es

FicherosTamañoFormatoVerDescripción
New horizons in breast cancer.pdf695.3KbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Atribución 4.0 Internacional